New drug combo for high-risk blood cancer transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of two chemotherapy drugs (bendamustine and cyclophosphamide) given before a stem cell transplant to help prevent graft-versus-host disease. It is for people with high-risk blood cancers who don't have a fully matched donor and will receive a partially matched transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-risk blood cancer (like acute myeloid leukemia, myelodysplastic syndrome, or chronic myeloid leukemia) that hasn't fully responded to treatment or has come back.
- You need a stem cell transplant (bone marrow or peripheral blood), but you don't have a fully matched sibling or unrelated donor — only a 5-9 out of 10 match is available.
- You are generally healthy enough to undergo a transplant (no severe other medical conditions).
- Your transplant will use stem cells from the donor's blood or bone marrow.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different drug combinations (BeFluBu and FluBuRux) used before a stem cell transplant from a half-matched (haploidentical) donor. The goal is to see which combination works better to prepare your body for the transplant and control your blood cancer.
This trial tests if a drug combo (cyclophosphamide, sirolimus, and ruxolitinib) works better than another combo (cyclophosphamide, sirolimus, and mycophenolate mofetil) to prevent graft versus host disease in people getting a stem cell transplant for certain blood cancers.
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
This trial tests two different combinations of medicines to prevent graft-versus-host disease (when donor cells attack your body) after a stem cell transplant. The goal is to see which approach works better for people with certain blood cancers or lymphomas.
This trial tests whether adding two drugs (ruxolitinib and decitabine) to the standard chemotherapy before a stem cell transplant can help prevent leukemia from coming back. It is for people with acute myeloid leukemia who have a suitable donor and are otherwise healthy enough for transplant.
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.